Olfactive Biosolutions Granted Patent for Next-Generation Daily Weight Loss Pill; Pivit™ is the First-to-Market Effective Daily Nonprescription Pill for Weight Loss

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Olfactive Biosolutions, the leader in adapting food molecules to treat chronic diseases, was today granted a patent for formulations of food molecules that cause significant weight loss when taken as a daily pill. The company’s Pivit supplement induces the simultaneous secretion of GLP-1, PYY and GIP, in U.S. patent US 12,290,550, Compositions for Treating Endocrine Diseases and Disorders. The company now has four granted patents that cover weight loss and blood sugar regulation.

The patent covers compositions of food molecules that together act as an oral small molecule triple receptor agonist, causing increased levels of GLP-1, PYY and GIP hormones clinically proven to lessen appetite and slow gastric emptying, and specifically relates to oral formulations of natural food molecules for treating diabetes mellitus and obesity by modulating ectopic olfactory, taste and related receptor activity.

Olfactive Biosolution’s first product under this patent is Pivit, a GLP-1 / PYY / GIP triple receptor agonist, similar to the class of drugs that have become blockbusters because of their weight-loss effects. But the GLP-1s on the market now are expensive, must be kept refrigerated and must be injected. The Pivit pill that produces similar or better results has the potential to become far more widely used, and since Pivit comprises common food molecules it is much cheaper to manufacture. Pivit can be taken without food and water restrictions. Pivit demonstrates statistically significant weight loss results and a safety profile superior to injectable GLP-1 medicines.

About 40 percent of Americans are obese, and more than 15 percent have diabetes, most of whom have Type 2, according to the Centers for Disease Control and Prevention. In the coming decades some 700 million people worldwide will have Type 2 diabetes and more than 1 billion will be affected by obesity.

“We are pioneering this exciting new space of the pharmacodynamics of natural food ligands and their effect on receptors, to bring better health to a large number of people and to address a wide range of chronic conditions,” said Nils Lommerin, President and CEO of Olfactive Biosolutions. “With the Pivit pill we can reach underserved populations around the world and inexpensively bring better health outcomes to millions and millions of people.”

“Olfactive Biosolutions has taken a novel approach to GLP-1-mediated weight control by using its technology to identify the foods we ingest that actually activate production of GLP-1 and other mediators that signal satiety,” said Dr. James Broach, Distinguished Professor and Chair, Department of Molecular and Precision Medicine at Penn State University and a noted expert on olfactory receptors. “As a result, the company can now provide directly to consumers an inexpensive and safe product that can broadly address the epidemic of diabetes and obesity,” he said.

Olfactory and taste receptors are not just in the nose and tongue, but everywhere in the body – including the lungs, the vasculature, the gut, brain, heart and kidneys.

These ectopic receptors influence GLP-1, PYY and GIP secretion, serotonin and dopamine secretion, blood pressure, muscle regeneration, bone remodeling, bronchodilation, kidney function and many other physiological pathways.

This approach promises the ability to bring health and wellness to large parts of the globe. Food molecules are cheap and plentiful and unlike pharmaceuticals, they have no known side effects and can be consumed on a long-term basis.

The Olfactive Biosolutions team has deep expertise in receptor protein science and the food & beverage industry. The company has several well-known biotechnology advisors from academia and the corporate world; its President and CEO is a former President, CEO and Director of Del Monte Foods.

Highlights

Innovative Mechanism of Action: Pivit is a groundbreaking triple agonist targeting GLP-1, PYY and GIP, synergistically enhancing insulin secretion, improving glucose homeostasis, and reducing appetite and food noise.

Significant Effectiveness: Consumer trials demonstrate Pivit's substantial efficacy, evidenced by notable reductions in body weight and improved glycemic control.

No Known Side Effects: Pivit has no known side effects. Side effects of injectable obesity drugs include diarrhea, indigestion, constipation, nausea and vomiting.

Broad Health Potential: Beyond glycemic control and weight reduction, Pivit shows promise in mitigating cardiovascular risk factors and addressing hypertension. Pivit could have potential benefits in positively affecting other components of the metabolic syndrome such as high triglycerides, low high-density lipoprotein cholesterol, increased blood pressure, and increased fasting sugars.

Pivit will be available as a supplement sold direct to consumers beginning September 2025. Food and beverage manufacturers will also add Pivit Weight Management to their consumer products, bringing benefits consistent with current prescription-only pharmaceuticals.

About Olfactive Biosolutions

Olfactive Biosolutions is the leader in harnessing food molecules to treat chronic diseases. It has developed world-leading receptor technology and expertise in both ectopic receptors in the gut, lungs, skin, heart, blood and elsewhere, and olfactory and taste receptors in the nose and tongue. Its unique technology demonstrates how ectopic receptors often perform the same physiological tasks as active pharmaceutical ingredients or APIs, and what ligands activate or inhibit them.

To learn more, visit https://olfactive.bio or follow us on LinkedIn.